Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrombolytic therapy for prevention of CTEPH after submassive pulmonary embolism
IRCT20190301042873N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jul 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of streptokinase, heparin and enoxaparin in pulmonary embolism (PE) and chronic thromboembolic pulmonary hypertension (CTEPH) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Incidence of chronic thromboembolic pulmonary hypertension. Started Jul 2020; status: completed.
02
Drugs
streptokinaseheparinenoxaparin
03
Conditions
pulmonary embolism (PE)chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on IRCT20190301042873N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190301042873N1.